MB Therapeutics: 3D printing at the heart of regional innovation
Innovation in the pharmaceutical sector is a collective journey. At MB Therapeutics, our mission is to transform patient care through 3D medicine printing. We recently hosted key regional stakeholders for a strategic update on our development.
Leading institutional and academic partners
We had the pleasure of hosting Philippe Augé (President of the University of Montpellier), Philippe Combette (Director of innovation at UM) et Frédéric Rimattei (Director General of Nîmes University Hospital). They were accompanied by Fabrice Salemi and Maxime Thorel, representing the Région Occitanie / Pyrénées Méditerranée, in coordination with Vice-President Jalil Benabdillah.
From left to right: Stéphane Roulon (CEO, MB Therapeutics), Frédéric Rimattei (Director General, Nîmes University Hospital), Ian Soulairol (CTO & Co-founder, MB Therapeutics), Philippe Augé (President, University of Montpellier), Philippe Combette (Director of Innovation, University of Montpellier).
A journey defined by regional excellence
This meeting highlighted the key milestones driving our growth:
- Academic roots: A strong partnership established from day one through a hosting agreement with the University of Montpellier, prior to moving into our new facility.
- Clinical validation: A close and practical collaboration with Nîmes University Hospital.
- National recognition: Our selection as a France 2030 regional winner, providing major support for industrial innovation in healthcare.
3D printing at the patient’s service
This meeting illustrates the vital link between academic research, the hospital environment, and regional institutions in transforming innovation into concrete solutions for patients.
